Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies
Xavier Leleu, Meral Beksaç, Takaaki Chou, Meletios A Dimopoulos, Sung‐Soo Yoon, H. Miles Prince, Luděk Pour, Tatiana Shelekhova, Ajai Chari, Monica Khurana, Mihaela Obreja, Ming Qi, Albert Oriol, David S. Siegel (2020). MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies. , 20, DOI: https://doi.org/10.1016/s2152-2650(20)30917-4.
Article32 days agoEfficacy and safety of weekly carfilzomib (70 mg/m<sup>2</sup>), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
Xavier Leleu, Meral Beksaç, Takaaki Chou, Meletios A Dimopoulos, Sung‐Soo Yoon, H. Miles Prince, Luděk Pour, Tatiana Shelekhova, Ajai Chari, Monica Khurana, Jianqi Zhang, Mihaela Obreja, Ming Qi, Albert Oriol, David S. Siegel (2020). Efficacy and safety of weekly carfilzomib (70 mg/m<sup>2</sup>), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. , 62(2), DOI: https://doi.org/10.1080/10428194.2020.1832672.
Article32 days agoEFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001
Xavier Leleu, Meral Beksaç, Takaaki Chou, Meletios A Dimopoulos, SS Yoon, H. Miles Prince, Ajai Chari, Albert Oriol, David S. Siegel, Monica Khurana, Ming Qi, Mihaela Obreja, Luděk Pour, Tatiana Shelekhova (2020). EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001. , 42, DOI: https://doi.org/10.1016/j.htct.2020.10.431.
Article32 days agoEfficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m<sup>2</sup> and once-weekly at 70 mg/m<sup>2</sup> in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001.
Xavier Leleu, Meral Beksaç, Takaaki Chou, Meletios A Dimopoulos, Sung‐Soo Yoon, H. Miles Prince, Luděk Pour, Tatiana Shelekhova, Ajai Chari, Monica Khurana, Mihaela Obreja, Ming Qi, Albert Oriol, David S. Siegel (2020). Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m<sup>2</sup> and once-weekly at 70 mg/m<sup>2</sup> in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001.. , 38(15_suppl), DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.8526.
Article32 days ago